Back to Journals » OncoTargets and Therapy » Volume 6

Epigenetic therapy: use of agents targeting deacetylation and methylation in cancer management

Authors Ho AS, Turcan S, Chan TA

Received 31 January 2013

Accepted for publication 25 February 2013

Published 21 March 2013 Volume 2013:6 Pages 223—232


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Allen S Ho,1 Sevin Turcan,1 Timothy A Chan1,2

1Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; 2Brain Tumor Center, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Abstract: The emergence of epigenetic mechanisms as key regulators of gene expression has led to dramatic advances in understanding cancer biology. Driven by complex layers that include aberrant DNA methylation and histone modification, epigenetic aberrations have emerged as critical processes that disrupt cellular machinery and homeostasis. Recent discoveries have already translated into successful clinical trials and improved patient care, with several agents approved for hematologic disease and others undergoing study. As the field matures, substantial challenges persist that will require resolution. These include the need to decipher more fully the interplay between the epigenetic and genetic machinery, patient selection and improving treatment efficacy in solid tumors, and optimizing combination therapies to counteract chemoresistance and minimize adverse effects. Here, we review recent progress in epigenetic treatments and consider their implications for future cancer therapy.

Keywords: epigenetics, cancer, acetylation, methylation, histone, transcription, tumor

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.